Aberraciones cromosómicas de tumores sólidos en Córdoba, Argentina. nº 1313 – (acts) – versión 28/9/05.

Aproximadamente una de cada cinco personas en el mundo mueren de cáncer. A pesar de los considerables avances en el tratamiento, incluyendo procedimientos de alta precisión en cirugía y protocolos detallados para rayo y quimioterapia, los tumores malignos son una de las causas de muerte más prominentes de la sociedad moderna. Las estrategias para el tratamiento dependen de un diagnostico preciso y temprano. No obstante algunos tumores son dificultosos para clasificarlos, desarrollando una incertidumbre en el pronóstico y tratamiento. Los tumores de tejidos blando y óseo son un grupo de neoplasias diverso y grande, que ocurren en todas las edades, normalmente sin un aparente factor etiológico. El diagnostico/ pronóstico puede ser complicado y el dilema del diagnóstico diferencial depende frecuentemente de los métodos histopatológicos y radiológicos. El presente proyecto intenta detectar las aberraciones cromosómicas en tumores sólidos utilizando las técnicas de biología molecular. Este método de detección es el más adecuado para diagnosticar y tratar eficientemente una gran cantidad de cánceres. Permite identificar alteraciones cromosómicas,tales como deleciones, translocaciones, amplificaciones y mutaciones que están asociadas con tipos específicos de tumores sólidos.

VeriStrat(®) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528.

BACKGROUND: VeriStrat(®) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. PATIENTS AND METHODS: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. RESULTS: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p=0.0027, HR=0.480, 95% confidence interval: 0.294-0.784). CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

HSC(F)05-2014 (PDF 201 KB)

Update to Procurement Guidance Note 03/11 - Award of Contracts without a Competition

Closure of Space for health - PEL(13)05 (PDF 38KB)

This Professional Estates Letter informs HSC bodies of the closure of the Space for Health information service and the availability of DHSPPS estates and facilities management policy on the DHSSPS website.

Annual Report to the Equality Commission 04-05 (PDF 187 KB)

The Department’s Evaluation and Equality Unit provides advice and guidance to colleagues throughout the Department who are planning and undertaking reviews and evaluations of programmes, services and policies, and provides guidance and information to support the policy-making processes. In carrying out this function the Unit has continued to help colleagues to mainstream equality considerations into decision-making, reviews and evaluations from the earliest stages of these processes. åÊ

Nursing & Midwifery Workforce Planning - Final Report Sept 05 (PDF 239 KB)

Nursing & Midwifery Workforce Planning - Final Report Sept 05